‘. Phase II data are snapshots of what this drug is able to ‘Swaby said. ‘Phase III clinical trials are in progress, which I think is the right next step for this drug. My patients in the study as well. ‘.
‘courtesy of you, the entire Kaiser Daily Health Policy Report view, search the archives, or sign up for email delivery at Kaiser Daily Health Policy Report is published for Reprinted imperial network. A free service of The Henry J. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.Forward-Looking StatementsThis press release contains certain forward-looking statements, which believed on the business of Bionovo, that can be by the use of forward – looking terminology such as identified ‘, ”expects ‘or similar expressions. Such forward looking statements include known and unknown to risks and uncertainties, including uncertainties relating to product design, the efficacy and safety, regulatory actions or delays, ability to obtain or keeping patents or other rights of the intellectual property, market acceptance, medical acceptance of third party refunds, future capital requests, competition in general and other factors which lead that of the actual results differ from the described in this as anticipated, believed, estimated or expected is.
‘Vaginal dryness is be a very painful, day to day, the quality of life care for via 50 percent of women in the menopause estrogen The only available FDA-approved treatment for women, the raise been shown the risks of an potentially lethal potentially fatal. And and uterine cancer, heart disease, stroke and thromboses, ‘said Dr. Tagliaferri. ‘Independent studies have revealed that the principal reason postmenopausal females failed prior to sexual activity being due vaginal dryness., Due the lack reliable treating options for these indications, and given the information we have developed from this drug candidate Dr.